About Us

Our mission is to develop innovative therapies for patients affected by rare neurological diseases, where treatment options are often limited, unavailable, or difficult to administer, impacting patient adherence and outcomes.

2013

Year of creation

5

Targeted diseases

4

drugs in development

Our Journey

2013

A spinoff of CEA, Theranexus was founded as a biotech company focused on rare neurological diseases through a proprietary R&D platform.

2017

The company went public on Euronext Growth Paris to support the development of its clinical pipeline.

2018-2023

Theranexus advanced its research programs with a focus on Batten-1 and patient-adapted formulations such as TX01, targeting Gaucher disease and Niemann-Pick type C. At the same time, the company expanded its ASO platform to address additional rare neurological diseases and some brain cancers.

2024

Theranexus signs a key partnership agreement with Exeltis (Insud Pharma group) for the distribution of TX01 in Europe and Latin America, with an expected commercialization starting in 2027.

Exeltis

2025

Theranexus became THX Pharma, marking a strategic shift toward an integrated pharma model, and focusing on the development, regulatory approval and global commercialization of its drugs, with an initial focus on TX01 and Batten-1.